| Name | Title | Contact Details |
|---|
GF Casting Solutions is a technologically pioneering development partner and manufacturer of cast and additive components for the global automotive industry, aerospace and energy markets as well as for off-highway vehicles. The highly complex lightweight components are manufactured in one of four manufacturing technologies (iron sandcasting; aluminum & magnesium die-casting; precision casting; additive manufacturing) and machined up to a ready-to-mount level. In close cooperation with our customers and partners, we develop the casting innovations of the future - from the initial concept to precise implementation and reliable validation. As one of four strong divisions of Georg Fischer AG, GF Casting Solutions plays a leading role in the development and series production of casting solutions and connects more than 3700 employees at 14 sites worldwide. Visit us on www.gfcs.com Imprint: GF Casting Solutions AG Amsler-Laffon-Strasse 9 8201 Schaffhausen Switzerland Legal form: Stock Corporation Represented by: Carlos Vasto, President GF Casting Solutions, Member of the Group Management Trade register of canton of Schaffhausen, No. CH-290.3.002.299-3 Value-added tax No. 290.019
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.